WNS Signs Contract Extension with Leading Pharmaceutical Company for High-End Research & Analytics S
WNS Signs Contract Extension with Leading Pharmaceutical Company for High-End Research & Analytics Services
MUMBAI, India--(BUSINESS WIRE)-- WNS (Holdings) Limited (NYS: WNS) , a leading provider of global Business Process Outsourcing (BPO) services, announced today that it has extended its contract with global pharmaceutical leader GlaxoSmithKline Services Unlimited (GSK), to deliver high-end research and analytics services.
"In a rapidly changing and increasingly competitive global economy, the ability to analyze large amounts of complex data to drive insight-based decisions is critical to success. WNS has been a trusted partner in delivering these high-value analytics solutions to GSK, and we are delighted to announce this contract extension with a recognized leader in the pharmaceutical industry," said Keshav R. Murugesh, Group CEO, WNS Global Services.
WNS enables its global clients to make critical business decisions leveraging its research and analytics expertise, deep industry knowledge and robust delivery capabilities. WNS currently has over 2,000 research and analytics professionals supporting areas such as customer lifecycle analytics, market and business research, strategy and decision support, demand forecasting, customer risk scoring, loss management modeling, and measurement and reporting.
WNS (Holdings) Limited (NYS: WNS) , is a leading global business process outsourcing company. WNS offers business value to 200+ global clients by combining operational excellence with deep domain expertise in key industry verticals including Travel, Insurance, Banking and Financial Services, Manufacturing, Retail and Consumer Packaged Goods, Shipping and Logistics and Healthcare and Utilities. WNS delivers an entire spectrum of business process outsourcing services such as finance and accounting, customer care, technology solutions, research and analytics and industry specific back office and front office processes. As of March 31, 2013, WNS had 25,520 professionals across 31 delivery centers worldwide including Costa Rica, India, Philippines, Poland, Romania, South Africa, Sri Lanka, United Kingdom and the United States. For more information, visit www.wns.com.
Safe Harbor Statement
This document includes information which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events. Factors that could cause actual results to differ materially from those expressed or implied are discussed in our most recent Form 20-F and other filings with the Securities and Exchange Commission. WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
WNS Global Services
Sumi Gupta, Public Relations
+91 (22) 4095 2263
David Mackey, Corporate SVP-Finance & Head of Investor Relations
KEYWORDS: United Kingdom United States Europe Asia Pacific North America New York India Ireland
The article WNS Signs Contract Extension with Leading Pharmaceutical Company for High-End Research & Analytics Services originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.